Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30229478 | 0.82 | SLC6A2 (0.39) | L3MBTL1SLC6A2SLC6A4SLC6A3GBA1 | |
| SCHEMBL996908 | 0.82 | L3MBTL1 (0.50) | L3MBTL1TAAR1SLC6A2SLC6A4SLC6A3 | |
| Benzyl Benzoate SCHEMBL7194408 | 0.82 | KMT2A (0.57) | L3MBTL1SLC6A2SLC6A3 | |
| SCHEMBL25836448 | 0.81 | SLC6A2 (0.40) | L3MBTL1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3100127 | 0.81 | SLC6A2 (0.40) | L3MBTL1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3100122 | 0.81 | SLC6A2 (0.40) | L3MBTL1TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11734399 | 0.78 | LTB4R (0.41) | TAAR1SLC6A2SLC6A4SLC6A3DDB1 | |
| SCHEMBL1673315 | 0.77 | TAAR1 (0.35) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL216883 | 0.75 | SLC6A2 (0.39) | TAAR1SLC6A2SLC6A4SLC6A3GBA1 | |
| SCHEMBL873745 | 0.74 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0435059-B1 | Retroviral protease inhibitors | HOECHST AG (DE) | 1997-11-05 | — | — | EP | claimed |
| US-5663139-A | VIRICIDE OLIGOPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-02 | — | — | US | claimed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | claimed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | claimed |
| EP-0410278-B1 | Renin inhibiting aminooligohydroxy-derivatives | HOECHST AG (DE) | 1994-01-19 | — | — | EP | claimed |
| US-5169841-A | Enzyme inhibitors, hypotensive agents, high enteral bioauailability | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | claimed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| CN-108473484-B | Compounds useful as TRPM8 modulators | 弗门尼舍公司 | 2021-06-29 | — | — | CN | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| US-5629431-A | Inhibitors of retroviral proteases | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |
| EP-0753540-A2 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
| EP-0688314-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-12-27 | — | — | EP | disclosed |
| WO-1994021604-A1 | PRODRUG DERIVATIVES OF ENZYME INHIBITORS WITH HYDROXYL GROUPS, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-09-29 | — | — | WO | disclosed |
| US-5169841-A | Enzyme inhibitors, hypotensive agents, high enteral bioauailability | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-12-08 | — | — | US | disclosed |
| EP-0254078-B1 | PYRAN DERIVATIVES | BASF Aktiengesellschaft (DE) | 1991-02-06 | — | — | EP | disclosed |
| EP-0254078-A1 | Pyran derivatives | BASF Aktiengesellschaft (DE) | 1988-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | L3MBTL1 4816/4885TAAR1 942/4885SLC6A2 748/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | L3MBTL1 4816/4885TAAR1 942/4885SLC6A2 748/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | L3MBTL1 4816/4885TAAR1 942/4885SLC6A2 748/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | L3MBTL1 4816/4885TAAR1 942/4885SLC6A2 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.